Bioelectronics Corp (BIEL)

[srinsocal]

Further confirmation of efficacy by 2 Universities & 1 Hospital in Rome

Current Evidence Using Pulsed Electromagnetic Fields in Osteoarthritis
Published: 28 March 2024

(1) Background: Osteoarthritis (OA) significantly impacts patients’ quality of life and negatively affects public healthcare costs. The aim of this systematic review is to identify the effectiveness of pulsed electromagnetic fields (PEMFs) in OA treatment across different anatomical districts, determining pain reduction and overall improvement in the patient’s quality of life. (3) Results: PEMF therapy demonstrated positive outcomes across various anatomical districts, primarily in knee osteoarthritis. Pain reduction, assessed through VAS and WOMAC scores, showed significant improvement (60% decrease in VAS, 42% improvement in WOMAC). The treatment duration varied (15 to 90 days), with diverse PEMF devices used. Secondary outcomes included improvements in quality of life, reduced medication usage, and enhanced physical function.

3.2. Type of PEMF Device
These studies investigated the utilization of both presently available PEMF devices on the market and outdated, no longer used equipment. The variety of PEMF devices employed in these studies introduced an additional layer of complexity to the analysis. [Table 2]. Devices such as those from the Bioelectronics Corporation (BioElectronics Corporation- Metropolitan Court Fredrick, MD, USA), Magcell Arthro (Physiomed Elektromedizin-Hutweide, Schnaittach, Germany), and XT-2000 B by the Better Health Corporation (Abbotsford, Victoria, Australia), each characterized by unique specifications like the frequency and intensity of the magnetic field, highlight the technological variability within PEMF therapy. For instance, the Bioelectronics Corporation’s device has a carrier frequency of 27.12 MHz and emits 1000 pulses per second.

4.4. Outcomes and Result Heterogeneity
The consistent focus on pain reduction as a primary outcome, measured using visual analog scales or disease-specific scales, indicates positive trends in PEMFs’ analgesic effects. Diverse secondary outcomes, including quality of life assessments, changes in analgesic and NSAID intake, and improvements in physical function, reflect the multifaceted impact of PEMF therapy on osteoarthritis.

https://www.mdpi.com/2077-0383/13/7/1959